Chengdu shengnuo bio technology is powerful, 200% of antithrombotic injection is the first to comment

Chengdu shengnuo biotechnology is powerful, 200% of antithrombotic injection is the first to comment

Recently, Chengdu shengnuo bio Co., Ltd. has been approved to produce etibatide injection (acceptance No. cyhs1700193), which is the first in China. According to the data of the Internet, the terminal growth rate of the product in China’s public medical institutions will exceed 200% in 2019.

Etibatide is a platelet glycoprotein Ⅱ B / Ⅲ a receptor antagonist. It can selectively and reversibly inhibit platelet aggregation. It is clinically used in the treatment of acute coronary syndrome (unstable angina pectoris / non ST segment elevation myocardial infarction). It has the characteristics of rapid onset, strong antiplatelet effect and reversible effect.

Figure 1: Sales of etibatide injection in China’s public medical institutions from 2015 to 2019 (unit: 100 million yuan)

Source: terminal competition pattern of China’s public medical institutions

According to the data from the Internet, the terminal growth rate of etibatide injection in China’s urban public hospitals, county-level public hospitals, urban community centers and township hospitals (hereinafter referred to as China’s public medical institutions) will grow by more than 200% in 2019, with hausen leading the market.

Chengdu shengnuo bio technology is powerful, 200% of antithrombotic injection is the first to comment

发表回复

您的电子邮箱地址不会被公开。 必填项已用*标注

Scroll to top